Data as of Sep 18, 2026 · Based on 3,315,446 AI responses across 10,525 prompts · See how Parse measures this
BIOPTIC is an AI-powered platform that automates discovery, diligence, and in-licensing of drug assets for biopharma, using integrated AI agents to triage, assess, and prioritize opportunities by combining molecular insights, clinical data, and deal economics. It scans 100+ languages and sources worldwide—from papers and filings to patents—to surface undervalued assets, enabling asset scouting, due diligence, and commercialization with autonomous real-time monitoring of trials, patents, and regulatory shifts. The system relies on proprietary models (B1 ligand-based, B2 sequence-based, B3 ADMET) and a curated data stack, with reinforcement learning and multi-agent QA to deliver decision-grade insights and quantifiable outputs across the pipeline.
Parse Score
Excerpts where BIOPTIC appeared in the AI's answer
bioptic.io uses AI models for ultra-large virtual screening and ranked hit lists.
BIOPTIC – ultra-large virtual screening capable of ranking billions of purchasable compounds and filtering for synthesizability and ADMET.
